1,000+ Opportunities
Find the right grant
Search federal, foundation, and corporate grants with AI — or browse by agency, topic, and state.
Alliance for Cancer Gene Therapy (ACGT) Research Grants is sponsored by Alliance for Cancer Gene Therapy (ACGT). ACGT funds scientific research to bring innovative treatment options using cancer cell and gene therapy, including CAR T-cell therapy, to people living with deadly cancers. A recent grant supported the development of remote-control CAR T-cell therapy.
Get a weekly digest of new grants like this
A free weekly digest of new foundation and federal funding opportunities as they're added to Granted. Unsubscribe anytime.
Or search similar grants →Extracted from the official opportunity page/RFP to help you evaluate fit faster.
Apply for Funding | Alliance for Cancer Gene Therapy Groundbreaking Research Apply for Funding Apply for research funding. Alliance for Cancer Gene Therapy current Request for Applications. 2026 ACGT Investigator Award in Cell and Gene Therapy for SOLID TUMOR CANCERS Applications are now closed 5-15-2026.
Alliance for Cancer Gene Therapy, Inc. (ACGT) funds breakthrough research that is transforming cancer treatment through cell and gene therapy. This ACGT grant award is for those conducting translational cell and gene therapy research specifically in solid tumor cancers . Frequently Asked Questions What types of grants are awarded?
Historically, Alliance for Cancer Gene Therapy has awarded clinical translation grants of $250,000 to $500,000 over two to three years, inclusive of a maximum of 10% indirect costs. Funds may be used at the recipient’s discretion for salary, technical assistance, supplies, animals or capital equipment, but may not support staff not directly related to the project, such as secretaries or administrative assistants.
Purchase of equipment is not allowed in the final year of the grant. Applicants must hold an MD, PhD, or equivalent degree and must be tenure-track or tenured faculty. While we recognize that there may be other excellent researchers not on a tenure-track, or not at medical schools or research centers, this is an eligibility requirement for application.
The investigator must be conducting original research as an independent faculty member. There are no citizenship restrictions, but research supported by the award must be conducted at academic medical centers or research centers located in the United States or Canada. If you already have an active ACGT Investigator Award, you are not eligible to apply until 24 months following the grant agreement’s effective date.
If a grant award is under a subsequent no-cost extension, it is unlikely that a second award would be made until the extension is completed. What is the review process? Members of our distinguished Scientific Advisory Council oversee the review and recommendation process.
All Letters of Intent (LOIs) are assessed by at least two members of the Council or their approved reviewers. Applicants whose LOIs are deemed responsive to the Request for Applications (RFA) and our mission are invited to submit full applications that include: biosketch, budget, research plan (10-page max), literature citations, and letter of reference.
Final applications are then carefully reviewed by the Council, which makes recommendations for final approval. What is the institutional policy? Grant funds are disbursed following execution of a grant agreement between the grantee institution and Alliance for Cancer Gene Therapy.
Who signs the application? Applications need to be signed by an appropriate representative of the institution, such as the Signing Official for Assurances in the Grants and Contacts Department and/or in the Legal Department. May I apply from an institution outside the United States?
Alliance for Cancer Gene Therapy has no citizenship restrictions, but research supported by its grants must be conducted at medical schools and research centers located in the United States or in Canada. Are literature citations part of the 10-page research plan limit? No. In addition to the 10-page research plan, an additional four pages are allowed for literature citations.
Can I revise my application after submission? No. Applications may be submitted only once, so please carefully read the instructions that appear throughout the application pages. If changes become necessary BEFORE the application deadline, please call Altum Proposal Central customer service at (-800) 875-2562.
No changes can be made AFTER the application deadline. Can I get funding alerts by email? Yes, please join our mailing list to receive updates about upcoming Requests for Applications.
Please join our mailing list to receive updates about Requests for Applications. Learn More About the Program --> “We are grateful for risk-taking organizations like Alliance for Cancer Gene Therapy that are willing to fund new ideas. If you want to fund the future of medicine, this is where to put your money.
” Icahn School of Medicine at Mount Sinai
According to the current listing, eligibility includes: Scientists developing gene and cell therapies for cancer, with a focus on glioblastoma, melanoma, sarcoma, ovarian, lung, prostate, and pancreatic cancers. Confirm the full requirements in the official notice before applying.
The current listing shows typical grant of $500,000. Verify award ceilings, matching requirements, and allowable costs in the official notice.
Alliance for Cancer Gene Therapy (ACGT) Research Grants is funded by Alliance for Cancer Gene Therapy (ACGT). Verify program details on the funder's official page before applying.
Start from the official opportunity page linked in this listing — it carries the sponsor's submission instructions.
BioStabilization Systems funds multi-party consortia under Other Transaction Authority across four phases, with hard down-selects that punish single-investigator labs and reward biotech-academic teams already deep into bioprocessing.
Read articleThe Breast Cancer Research Foundation launched a $100 million venture philanthropy fund at CGI on September 22, 2026, seeded with $23 million and aiming at 20 to 30 companies. Here is what the structure actually means for investigators, for startups in the valley of death, and for every disease foundation now weighing the same move.
Read articleCDC-RFA-DP-27-0023 puts the National Breast and Cervical Cancer Early Detection Program, the National Comprehensive Cancer Control Program, and the National Program of Cancer Registries into a single competition closing February 5, 2027. Three statutorily separate eligibility pools, one application deadline, and an award count that maps onto the incumbent footprint. Here is how to read that.
Read article